Metabolic Syndrome and Combination Antiretroviral Therapy in HIV Patients in Periurban Hospital in Ghana: A Case-Control Study

Table 5

Association between metabolic syndrome and cART regimen in cART-treated HIV patients.

	MetS		Unadjusted OR (95% CI)		Adjusted OR (95% CI)
	Absent	Present
TDF-based	42 (75)	58 (56.9)	0.44 (0.21–0.9)	0.025	0.41 (0.18–0.98)	0.044
AZT-based	12 (21.4)	44 (43.1)	2.78 (1.32–5.88)	0.007	2.63 (1.11–6.2)	0.028
EFV-based	42 (75)	60 (58.8)	0.48 (0.23–0.98)	0.044	0.51 (0.21–1.2)	0.508
NVP-based	12 (21.4)	34 (33.3)	1.83 (0.86–3.92)	0.118	1.83 (0.75–4.46)	0.182
LPV/r-based	4 (7.1)	8 (7.8)	1.62 (0.46–5.74)	0.458	1.5 (0.27–8.31)	0.64

Adjusted for age, gender, marital status, alcohol and smoking status, employment, educational level. and CD4 cell level. MetS, metabolic syndrome; AZT, zidovudine; EVF efavirenz; LPV/r, Lopinavir/ritonavir; NVP, nevirapine; TDF, tenofovir. Lamivudine was part of the medication regimen for 154 (97.5%) patients, and hence, we did not analyse it. Stavudine and emtricitabine were taken by 2 and 4 patients, respectively, and hence, we did not include them in our analyses.